<b>Background:</b> Our study retrospectively investigated the therapeutic effects of SGLT2 inhibitors on multiple outcomes in patients with Type 2 Diabetes, capitalizing on the agent's proven benefits in glycemic, cardiovascular, and renal systems. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.